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Alishekevitz et al. now find that
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treated tumors. At the treated tumor site,
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lymphangiogenesis and subsequent
metastasis via the VEGF-C/VEGFR3 axis.
Blocking VEGFR3 in treated tumors
hinders metastasis through the inhibition
of pro-metastatic macrophage activity.
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While chemotherapy strongly restricts or reverses tu-
mor growth, the response of host tissue to therapy
can counteract its anti-tumor activity by promoting
tumor re-growth and/or metastases, thus limiting
therapeutic efficacy. Here, we show that vascular
endothelial growth factor receptor 3 (VEGFR3)-ex-
pressing macrophages infiltrating chemotherapy-
treated tumors play a significant role in metastasis.
They do so in part by inducing lymphangiogenesis
as a result of cathepsin release, leading to VEGF-C
upregulation by heparanase. We found that macro-
phages from chemotherapy-treated mice are
sufficient to trigger lymphatic vessel activity and
structure in naive tumors in a VEGFR3-dependent
manner. Blocking VEGF-C/VEGFR3 axis inhibits the
activity of chemotherapy-educated macrophages,
leading to reduced lymphangiogenesis in treated
tumors. Overall, our results suggest that disrupting
the VEGF-C/VEGFR3 axis not only directly inhibits
lymphangiogenesis but also blocks the pro-metasta-
tic activity of macrophages in chemotherapy-treated
mice.
INTRODUCTION
One of the most challenging obstacles and leading cause of
death in breast cancer patients is the outburst of metastatic
disease that may occur years after the removal of the primary1344 Cell Reports 17, 1344–1356, October 25, 2016 ª 2016 The Auth
This is an open access article under the CC BY-NC-ND license (http://tumor. Lymph node involvement at time of diagnosis in the
absence of distant metastatic disease (i.e., locally advanced
diseases) significantly reduces survival rate (Fisher et al.,
1983). The lymphatic system serves as a major route for
tumor cells disseminating from the primary tumor site. Dissem-
inated tumor cells can be transported to the regional
lymph node, where they can either lodge and metastasize or
metastasize through the lymph nodes to remote areas (Stacker
et al., 2002). Vascular endothelial growth factor receptor
(VEGFR) 3 is the key receptor that regulates lymphangiogene-
sis. It can bind both VEGF-C and VEGF-D (Sleeman and
Thiele, 2009). The expression of VEGF-C by tumors, in partic-
ular, correlates with poor prognosis for a wide variety of
cancers, in part due to an increase in lymphangiogenesis
(Alitalo and Detmar, 2012). Increased VEGF-C levels induce
intra-tumoral lymphangiogenesis, resulting in significantly
enhanced metastasis to regional lymph nodes and to lungs
(Skobe et al., 2001). As a consequence, the combined neutral-
ization of VEGF-C and VEGF-D by soluble VEGFR3 resulted in
a complete abolishment of lymphangiogenesis (Ma¨kinen et al.,
2001).
Besides the cytotoxic effect of chemotherapy that ultimately
kills proliferating tumor cells, it has been recently reported that
chemotherapy can induce several host effects that can facili-
tate tumor growth and metastasis, thereby limiting the anti-
tumor activity of the drug (for review, see Shaked, 2016).
Mice treated with paclitaxel (PTX) succumb to breast cancer
metastasis earlier than mice treated with vehicle control in a
pulmonary metastatic model. The secretion of matrix metallo-
proteinase 9 (MMP9) by bone-marrow-derived cells (BMDCs)
colonizing treated tumors is a possible inducer of the metasta-
tic process (Gingis-Velitski et al., 2011). In addition, myeloidor(s).
creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. VEGF-C Is Elevated in Plasma and Tissue following Paclitaxel Chemotherapy
(A) Non-tumor-bearing BALB/c mice (n = 5/group) were treated with 25 mg/kg PTX or vehicle control (Veh). After 24 hr, blood was drawn and plasma was
separated. Bone marrow was flushed from the femurs, and cells were grown in culture from which conditioned medium (CM) was collected. Lungs, liver, spleen,
and brain were harvested and lysates were prepared. Levels of VEGF-C were evaluated in all specimens using ELISA.
(B) Blood was drawn from breast carcinoma patients (n = 12) at baseline and 24 hr after the first treatment with PTX. Plasma was evaluated for VEGF-C levels.
(C) Breast tumor specimens obtained from patients before (baseline) and after chemotherapy were stained for VEGF-C (red). Scale bar, 100 mm. The percentage
of positive pixels was determined and plotted (n = 6 sample pairs). Error bars indicate SD. *p < 0.05; **0.01R p > 0.001; ***p% 0.001 (two-tailed Student’s t test).cells and macrophages have also been shown to contribute to
tumor re-growth by promoting drug resistance. For example,
Shree et al. demonstrated that macrophages from PTX-
treated mice contribute to breast cancer resistance to therapy
via the secretion of cathepsins (Shree et al., 2011). Others
demonstrated that following anti-cancer therapies, macro-
phages limit the anti-tumor efficacy of the therapy sometimes
through unknown mechanisms (Timaner et al., 2015; Welford
et al., 2011). Thus, these collective studies suggest that
host cells, in response to therapy, generate pro-metastatic
and pro-tumorigenic effects that promote tumor regrowth,
metastasis, and resistance to therapy.
In the current study we investigated the role of the VEGF-C/
VEGFR3 axis in tumor spread following PTX chemotherapy.
We found that VEGFR3 expressed by chemotherapy-activated
macrophages contributes to lymphangiogenesis largely by
promoting the secretion of cathepsins, leading to increased
heparanase activity. This, in turn, induces the expression of
VEGF-C, ultimately leading to lymphangiogenesis and subse-
quently metastasis.RESULTS
Paclitaxel Induces VEGF-C Expression
Our previous studies indicate that chemotherapy administered
at conventional doses increases the levels of several circulating
growth factors (Shaked et al., 2008; Shaked et al., 2009). We
used a protein array to analyze plasma from non-tumor bearing
BALB/c mice 24 hr after the administration of PTX chemo-
therapy. VEGF-C levels were substantially increased in the
plasma of PTX-treated mice in comparison to control mice
(data not shown). In light of the known role of VEGF-C in tumor
lymphangiogenesis and metastasis (Mandriota et al., 2001;
Skobe et al., 2001), we further investigated its expression and
functional role in response to chemotherapy. We found a signif-
icant increase in the levels of VEGF-C in plasma, lungs, and
spleen, as well as conditionedmedium of BMDCs of PTX-treated
mice in comparison to vehicle-treatedmice (Figure 1A). Similarly,
VEGF-C levels were elevated in the plasma of breast cancer pa-
tients (n = 12) 24 hr after PTX treatment when compared to base-
line levels (Figure 1B). Furthermore, tissue derived from tumorsCell Reports 17, 1344–1356, October 25, 2016 1345
Figure 2. Elevation in Lymphatic Endothelial Cell Activity following Paclitaxel Therapy
(A and B) Plasmawas drawn from non-tumor-bearing BALB/c mice 24 hr after they were treated with vehicle (Veh) or PTX (n = 3mice/group). Half the plasma from
Veh- or PTX-treated mice was depleted of VEGF-C by immunoprecipitation with neutralizing anti-VEGF-C antibodies. (A) Migration and invasion of lymphatic
endothelial cells (LECs) were tested in the presence of the plasma samples using the Boyden chamber assay as described in Experimental Procedures. The
number of invading andmigrating cells per field was counted and plotted (n = 15/group). (B) LECs were seeded ontoMatrigel-coated plates and cultured for 24 hr
in growth medium supplemented with 10% plasma from vehicle- or PTX-treated mice. Tube formation was assessed. Representative phase contrast images are
shown. The number of bifurcations was counted (n = 12 fields/group). Scale bar, 200 mm. N.D., non-detectable.
(C) 4T1 and LLC cells were implanted in BALB/c and C57Bl/6 mice, respectively (n = 5/group). When tumors reached a size of 500 mm3, treatment with vehicle,
PTX, anti-VEGFR3 antibodies (31C1), or the combination of PTX and 31C1 was initiated. After 3 days, tumors were harvested and sections were prepared and
stained for LYVE-1, a LEC marker (red). DAPI was used to stain nuclei (blue). Scale bar, 200 mm. The number of lymphatic vessels in the tumors was counted per
field (n = 20/ group). Error bars indicate SD. ***p% 0.001 (one-way ANOVA followed by Tukey’s post hoc test).of chemotherapy-treated breast cancer patients exhibited signif-
icantly increased VEGF-C expression in comparison to baseline
biopsy specimens extracted before treatment with chemo-
therapy (n = 6) (Figure 1C). Of note, treatment with FOLFOX
and gemcitabine, but not cisplatinum chemotherapy, increased
VEGF-C levels in the plasma, lungs, and conditioned medium
of BMDCs of non-tumor-bearing mice (Figure S1). Overall, these
results demonstrate that acute administration of certain chemo-
therapy drugs such as PTX induces a significant increase in
VEGF-C levels in tumors, plasma, and various organs
Paclitaxel-Induced VEGF-C Expression Promotes
Lymphatic Endothelial Cell Activity In Vitro and In Vivo
To determine whether the induction in VEGF-C levels in the
plasma of PTX-treated mice alters lymphatic endothelial cell
(LEC) activity, we tested LEC migration, invasion, and tube for-
mation in the presence of plasma from control or PTX-treated
mice. All three processes were enhanced in the presence of
plasma fromPTX-treatedmice compared to plasma from vehicle1346 Cell Reports 17, 1344–1356, October 25, 2016control mice. Notably, when VEGF-C was depleted from plasma
of PTX-treated mice by immunoprecipitation, the enhancement
of LEC invasion and migration was completely abolished, sug-
gesting that PTX-induced LEC activity is primarily regulated by
VEGF-C (Figures 2A and 2B).
VEGFR3 is the major receptor for VEGF-C-induced lymphan-
giogenesis (Kukk et al., 1996). We therefore assessed lymphan-
giogenesis in tumors of PTX-treated mice in the presence of
VEGFR3-specific antibodies (31C1) that block receptor function
(Matsumoto et al., 2013). To this end, 4T1 and Lewis lung carci-
noma (LLC) tumors implanted in mice were allowed to grow until
they reached 500mm3, at which point treatment with PTX and/or
31C1 was initiated. After 3 days, tumors were removed and tu-
mor sections were stained with LYVE-1 antibody for the detec-
tion of lymphatic vessels. In control and 31C1-treated mice,
lymphatic vessels were localized to the periphery of the tumors.
In contrast, in PTX-treated mice, lymphatic vessels were found
both at the periphery and in the tumor center, and their number
was significantly increased. This effect was reversed in mice
Figure 3. Tumor Growth and Metastasis in
Mice Treated with Paclitaxel and/or 31C1
(A) 8- to 10-week-old female BALB/c mice
(n = 5/group) were orthotopically implanted with
4T1 cells into the mammary fat pad (0.5 3 106).
When tumors reached a size of 300 mm3, treat-
ment with vehicle, PTX, 31C1, or a combination of
the two drugs was initiated.When tumors reached
endpoint (1,000 mm3), mice were sacrificed.
Lungs were removed and lung sections were
stained with H&E and assessed for metastasis.
Metastatic lesions per magnified field were
counted (n = 15 fields/ group). Red arrows point at
micrometastases. Scale bar, 200 mm.
(B) LM2-4 human breast carcinoma cells (2 3 106)
were implanted into the mammary fat pad of 8-
to 10-week-old female CB.17 SCID mice
(n = 5/group).When tumors reached100–150mm3,
treatment with PTX and/or 31C1 was initiated. Pri-
mary tumor growth was measured and plotted.
(C) In a parallel experiment, 3 days after PTX
therapy, tumors were resected and mouse sur-
vival was monitored (n = 6–7 mice/group). A Ka-
plan-Meier survival curve was plotted.
(D) The resected primary tumors (from C) were
stained for LYVE-1 (red). DAPI was used to stain
nuclei (blue). Scale bar, 200mm. The number of
lymphatic vessels in the tumors was counted per
field (n = 20/ group).
(E) Vehicle (Veh), PTX, 31C1, or a combination of
the two drugs was administered to BALB/c mice.
After 24 hr, mice were injected with 25 3 104 4T1
cells through the tail vein to generate pulmonary
experimental metastasis. Mouse survival was
monitored and a Kaplan-Meier survival curve was
plotted (n = 7–8 mice/group). Error bars indicate
SD. *p < 0.05; ***p % 0.001 (one-way ANOVA
followed by Tukey’s post hoc test).treated with a combination of PTX and 31C1 (PTX+31C1). Of
note, the single dose of 31C1 monotherapy had a negligible
anti-lymphangiogenesis effect at this time point (Figure 2C).
Taken together, the in vitro and in vivo results suggest that
PTX promotes lymphangiogenesis throughout the VEGF-C/
VEGFR3 axis, in part via host effects.
Blocking the VEGF-C/VEGFR3 Pathway in Mice Treated
with PTX Inhibits Primary Tumor Growth andMetastasis
We next asked whether the blockade of the VEGF-C/VEGFR3
pathway following PTX therapy inhibits tumor cell dissemination
from the primary tumor and its colonization at metastatic sites.
To test tumor cell dissemination, 4T1 cells implanted into the
mammary fat pad of BALB/c mice were allowed to grow until
they reached 300 mm3, at which point, treatment with PTX
and/or 31C1 was initiated. At end point for each group, lungs
were removed and assessed for micrometastases. Mice treated
with PTX exhibited a significant increase in the number of meta-
static lesions when compared to control mice. This effect was
reversed in mice treated with a combination PTX and 31C1 (Fig-
ures 3A and S2).
We next performed similar experiments using the metastatic
LM2-4 cell line. LM2-4 cells were implanted into the mammary
fat pad of severe combined immunodeficiency (SCID) mice.When tumors reached 100–150 mm3, treatment with PTX and/or
31C1 was initiated. Primary tumor growth of mice treated with
PTX and 31C1 was significantly delayed compared to all other
treatment groups (Figure 3B). Furthermore, mouse survival was
significantly increased when the primary tumors were resected
3 days after PTX and/or 31C1 therapy (Figure 3C). In addition,
the tumors in control, 31C1, and PTX+31C1 treatment groups
exhibited a peripheral lymphatic vessel phenotype, in contrast
to tumors from the PTX monotherapy group in which lymphatic
vessels were both peripherally and centrally distributed (Figures
3D and S2B). These results are comparable to those shown
in Figure 2C. In a parallel experiment, when the control
group reached endpoint, lungs from all groups were removed
and evaluated for metastatic lesions. Control mice exhibited
an increased number of lesions in comparison to PTX- or
PTX+31C1-treated groups (Figure S2C). Primary tumor growth
and lymphatic vessel phenotypes were comparable in the
A549 human lung carcinoma model (Figures S2D and S2E). Of
note, tumor growth and the lymphatic vessel phenotype in tu-
mors frommice treated with isotype control antibody was similar
to that in vehicle control mice (Figure S2F; data not shown).
To test whether blocking the VEGF-C/VEGFR3 axis affects tu-
mor cell seeding in the lungs, we used an experimental lung
metastasis assay. BALB/c mice were treated with PTX and/orCell Reports 17, 1344–1356, October 25, 2016 1347
Figure 4. VEGF-C and VEGFR3 Expression
in Macrophages from Paclitaxel- and/or
31C1-Treated Mice
(A) Peritoneal macrophages were harvested from
non-tumor-bearing mice (n = 4/group) treated with
vehicle (Veh), PTX, 31C1, or a combination of the
two drugs and grown in culture. The level of
VEGF-C in the conditioned medium was assessed
by ELISA.
(B–D) 4T1 tumors were grown in BALB/c mice
(n = 4/group) until they reached 500 mm3, at which
point mice were treated with vehicle (Veh), PTX,
31C1, or a combination of the two drugs. After
3 days, tumors were harvested and tumor sections
were stained with F4/80 (a specific macrophage
marker, red). DAPI was used to stain nuclei (blue).
Scale bar, 200mm (B). The number of F4/80-posi-
tive cells per field was counted in the tumors
(n = 15 fields/group) (C). In a parallel experiment,
the harvested tumors (n = 4/group) were prepared
as single-cell suspensions, stained (for VEGFR3,
F4/80, and LYVE-1), and analyzed by flow cy-
tometry. The number of tumor-associated, viable
VEGFR3-expressing macrophages and viable
VEGFR3-expressing lymphatic endothelial cells was calculated based on the percentage of F4/80+/VEGFR3+/7AAD or LYVE1+/VEGFR3+/7AAD cells,
respectively, per 10,000 cells (D). Error bars indicate SD.
*p < 0.05; **0.01R p > 0.001; ***p% 0.001 (one-way ANOVA followed by Tukey’s post hoc test).31C1. After 24 hr, themicewere injectedwith 4T1 cells via the tail
vein, and survival was monitored. The results show that mice
primed with PTX succumbed to metastasis earlier than control
mice (Figure 3E), in line with a previous study (Gingis-Velitski
et al., 2011). However, mice treated with 31C1 alone or a combi-
nation of PTX+31C1 exhibited seeding properties similar to PTX-
treated mice. Taken together, these results suggest that the
VEGF-C/VEGFR3 axis inhibits tumor cell dissemination from
the primary tumor but does not affect seeding in PTX-treated
mice. Importantly, the therapeutic benefit of the combination
therapy of PTX and 31C1 was greater than PTX monotherapy
in both primary tumor and metastatic disease models.
Upregulation of VEGF-C byMacrophages Contributes to
Lymphangiogenesis in PTX-Treated Tumors
We next asked whether macrophages play a role in chemo-
therapy-induced metastasis through the VEGF-C/VEGFR3
pathway. To this end, peritoneal macrophages were extracted
from non-tumor-bearing mice, and after 48 hr in culture, the level
of VEGF-C in the conditioned medium was evaluated. VEGF-C
levels were significantly increased in the conditioned medium
of macrophages from PTX-treated mice compared to all other
treatment groups. This effect was reversed in conditioned
medium of macrophages obtained from mice treated with
PTX+31C1. Of note, a slight but significant increase in VEGF-C
levels was also observed in macrophages from mice treated
with 31C1, an effect that was completely blocked when mice
were treated with PTX+31C1, for reasons that are not clear (Fig-
ure 4A). Furthermore, no differences in VEGF-C levels were
observed in a parallel in vitro experiment in which PTX and/or
31C1 were added directly to macrophage cultures, suggesting
that the minimal increase in VEGF-C following PTX therapy is
not related to the direct cytotoxic effect of the drugs (Figure S3A).1348 Cell Reports 17, 1344–1356, October 25, 2016When focusing on VEGFR3, we found that a portion of peritoneal
macrophages express VEGFR3, in line with a previous study
(Zhang et al., 2014) (Figure S3B). However, the VEGFR3 expres-
sion levels were not affected in peritoneal macrophages from
mice treated with PTX and/or 31C1 (Figure S3C). Although peri-
toneal macrophages have been extensively studied in the
context of cancer, they are not ‘‘true’’ tumor-associated macro-
phages (Hagemann et al., 2009). We therefore evaluated the
level of VEGFR3-expressing macrophages in treated tumors.
We found that the number of macrophages infiltrating 4T1 tu-
mors 3 days after PTX therapy was substantially and significantly
increased compared to the PTX+31C1 group (Figures 4B and
4C). Importantly, the percentages of viable VEGFR3-expressing
macrophages and lymphatic endothelial cells, isolated from
mice bearing A549 tumors (from Figure S2D) treated with PTX
and/or 31C1, were significantly higher in mice treated with PTX
than in all other groups (Figures 4D and S3D). These results sug-
gest that macrophages expressing VEGFR3 infiltrate tumors in
response to PTX therapy.
To further test the effect of macrophages on PTX-dependent
metastasis and lymphangiogenesis, we performed a co-implan-
tation experiment using tumor cells and macrophages. Perito-
neal macrophages obtained from non-tumor-bearing BALB/c
mice treated with PTX and/or 31C1 were co-implanted with
4T1 tumor cells in a 1:1 ratio into the mammary fat pad of naive
mice (Figure 5A). Tumor growth was monitored over time. Mice
co-implanted with macrophages from PTX-treated mice ex-
hibited a trend towards larger tumors when compared to those
co-implanted with macrophages from control mice or from
mice treated with PTX+31C1, although these results did not
reach statistical significance (Figure 5B). At endpoint of the con-
trol group, primary tumors and lungs were removed and further
assessed for lymphangiogenesis and metastasis, respectively.
(legend on next page)
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Similar to the results shown in Figure 2C, the number of tumor
lymphatic vessels (stained for LYVE-1 and podoplanin) was
significantly higher in mice co-implanted with macrophages
from PTX-treated mice than in control or combination-treated
mice. These vessels were localized at the center of the tumor,
whereas tumors of mice co-implanted with macrophages from
control or combination-treated mice exhibited a peripheral
lymphatic vessel distribution (Figures 5C and S4A). Furthermore,
more metastases were observed in the lungs of mice co-
implanted with macrophages from PTX-treated mice than in
mice co-implanted with macrophages from the control or
PTX+31C1-treated group (Figure 5D). However, implantation of
macrophages frommice treated with VEGFR1 or VEGFR2 block-
ing antibodies (MF1 and DC101, respectively) in the presence of
PTX did not restore lymphatic vessel distribution to the periph-
ery. The PTX+DC101 group exhibited an intermediate peripheral
lymphatic vessel phenotype (Figure S4B), suggesting that the
effect is mostly specific to the VEGFR3 pathway. In addition, a
significant increase in mortality was observed in mice co-im-
planted with 4T1 cells and macrophages from PTX-treated
mice when compared to mice co-implanted with 4T1 cells
and control macrophages or macrophages from PTX+31C1-
treated mice (Figure 5E). Notably, no significant difference in
endothelial microvessel density was observed among all treat-
ment groups at the time point tested, ruling out the possibility
that increased metastasis is associated with angiogenesis in
our model (Figure S4C).
Next, we asked whether the link between macrophages and
the lymphangiogenesis phenotype following PTX therapy is
direct. To this end, we implanted BALB/c mice with 4T1 tumors
andwhen tumors reached a size of 350mm3,macrophages were
depleted, using clodronate-containing liposomes (clodrolip).
Macrophage depletion was verified in the spleens of clodrolip-
treated mice (Figure S4D). After 72 hr, mice were treated with
PTX with or without recombinant VEGF-C administered at a
dose of 50 mg/mouse per day for 3 sequential days. Sequential
VEGF-C administration was necessary in order to maintain
increased VEGF-C levels in the circulation due to its short half-
life (Veikkola et al., 2001). Tumors were removed on day 4
following PTX treatment and examined for lymphatic vessels.
Macrophage-depleted mice treated with PTX and control mice
exhibited similar numbers of peripherally distributed lymphatic
vessels, in contrast to PTX-treatedmice, in which lymphatic ves-
sels were significantly greater in number and distributed centrallyFigure 5. Macrophages from Mice Treated with Paclitaxel Promote Ly
(A–D) Peritoneal macrophages obtained frommice treatedwith vehicle (Veh), PTX,
4T1 cells into mice in a 1:1 ratio (0.5 3 105 cells) (n = 5 mice/group). A schematic
was assessed regularly until mice from control group reached endpoint (B). Sub
lymphatic vessels using anti-LYVE-1 antibodies (red) and nuclei were stained with
assessed for metastasis. Metastatic lesions per magnified field were counted (n
(E) In a parallel experiment, peritoneal macrophages obtained from mice treat
orthotopically co-implanted with 4T1 cells into mice in a 1:1 ratio (0.53 105 cells) (
curve was plotted.
(F) 4T1 cells were orthotopically implanted into the mammary fat pad of BALB/c
intraperitoneally with empty liposomes or clodronate-containing liposomes (clod
vehicle control, PTX, or PTX and recombinant VEGF-C (50 mg/mouse per day) as d
tumor sections were stained for LYVE-1 (red) and DAPI (blue). Scale bar, 200 mm
*p < 0.05; **0.01R p > 0.001; ***p% 0.001 (one-way ANOVA followed by Tukey
1350 Cell Reports 17, 1344–1356, October 25, 2016within the tumor. When macrophage-depleted, PTX-treated
mice were also injected with recombinant VEGF-C, the
lymphatic vessel distribution and number were restored to that
of PTX-treated mice (Figures 5F and S4E). In addition, levels of
plasma VEGF-C were assessed in non-tumor-bearing BALB/c
mice 72 hr after they were depleted of macrophages and 24 hr
after they were treated with PTX. VEGF-C plasma levels were
not significantly different from controls in mice depleted of mac-
rophages regardless of PTX therapy (Figure S4F). Taken
together, these results indicate that the lymphangiogenesis
phenotype in tumors from mice treated with PTX is primarily
regulated by macrophages, an effect that can be completely
abolished by blocking VEGFR3 specifically on macrophages.
Macrophages Enhance Heparanase Activity via
Cathepsins in a VEGFR3-Dependent Manner in
Response to Paclitaxel
Previous studies indicate that heparanase upregulates VEGF-C
expression, thus promoting metastasis via the lymphatic system
(Cohen-Kaplan et al., 2008). We therefore assessed heparanase
activity in peritoneal macrophages collected from mice treated
with PTX and/or 31C1. The level of endogenous heparanase
activity was 2-fold higher in conditioned medium of macro-
phages from mice treated with PTX or PTX+31C1 than in control
mice (Figure 6A). Notably, heparanase enzymatic activity was
5-fold higher following exogenous addition of the 65-kDa latent
enzyme to the conditioned medium of macrophages from mice
treated with PTX relative to the control group, an effect that
was blocked in the PTX+31C1-treated group (Figure 6B). Thus,
blocking VEGFR3 inhibits the activation of exogenous latent
heparanase, but not the endogenous enzyme, in macrophages
from PTX-treated mice.
Macrophages secrete cathepsins in response to PTX (Shree
et al., 2011). Since cathepsins cleave pro-heparanase into its
active form (Arvatz et al., 2011), and heparanase upregulates
VEGF-C expression (Cohen-Kaplan et al., 2008), we next asked
whether PTX-induced cathepsin release from macrophages
indeed contributes to the high VEGF-C expression in tumors.
To this end, conditioned medium of peritoneal macrophages
from PTX or PTX+31C1-treated mice was evaluated for its ability
to activate exogenous latent heparanase in the presence or
absence of cathepsin inhibitor. The results show that blockade
of cathepsins inhibited the activation of exogenous latent hepar-
anase incubatedwith conditionedmedium ofmacrophages frommphangiogenesis in Therapy-Naive Tumors
31C1, or a combination of the two drugs were orthotopically co-implantedwith
representation of the experimental procedure is provided in (A). Tumor growth
sequently, tumors and lungs were removed. Tumor sections were stained for
DAPI (blue). Scale bar, 200 mm (C). Lung sections were stained with H&E and
= 15/ group). Red arrows point at micrometastases. Scale bar, 200 mm (D).
ed with vehicle (Veh), PTX, 31C1, or a combination of the two drugs were
n = 8 mice/group). Mouse survival was monitored, and a Kaplan-Meier survival
mice (n = 6 mice/group). When tumors reached 350 mm3, mice were injected
rolip) in order to deplete macrophages. After 3 days, mice were treated with
escribed in Experimental Procedures. Tumors were removed 3 days later, and
. Error bars indicate SD.
’s post hoc test).
Figure 6. Heparanase and Cathepsin Activity Is Increased in Macrophages from Paclitaxel-Treated Mice in a VEGF-C/VEGFR3-Dependent
Manner
(A) Peritoneal macrophages were obtained from mice treated with vehicle (Veh), PTX, 31C1, or a combination of the two drugs (n = 3 mice/group). Conditioned
media of the macrophage cultures were collected after 24 hr, adjusted to pH 6.2, and applied to sulfate-labeled ECM dishes. Heparanase enzymatic activity was
determined as described in Experimental Procedures.
(B) Conditioned medium of macrophages from treatment groups described in (A) was supplemented with latent heparanase (1 mg/mL), and heparanase activity
was determined as in (A).
(C) Conditioned medium of macrophages from PTX-treated mice (n = 3) supplemented with latent heparanase (1 mg/mL), 31C1, cathepsin inhibitor, or a com-
bination of the two drugs was applied to sulfate-labeled ECM dishes. Heparanase activity was determined.
(D) Macrophages from control mice or mice treated with PTX in the presence or absence of VEGF-C, cathepsin inhibitor GB111-NH2, and 31C1 were collected
(n = 4 mice/group). Conditioned medium from macrophage cultures was collected and treated with GB123, a fluorescent-activity-based probe. In-gel fluo-
rescence was scanned. The black arrow indicates the fluorescent cathepsin activity band. The experiment was repeated three times. A representative western
blot is provided with densitometry analysis of the three biological repeats.
(legend continued on next page)
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Figure 7. The Lack of Heparanase or Inhibi-
tion of Cathepsins in Paclitaxel-Treated Tu-
mors Alters Lymphatic Vessel Phenotype
(A) LLC cells (0.5 3 106) were implanted into the
flanks of either chimeric wild-type mice, which were
used as recipients of heparanase/ bone marrow
cells (WT-BMhep/; n = 5 mice/group), or hepar-
anase / mice, which were used as recipients of
wild-type bone marrow cells (Hep/BMwt, n = 5
mice/group). When tumors reached 500 mm3,
treatment with PTX or PTX+31C1was initiated. After
3 days, tumors were removed, and tumor sections
were stained for podoplanin (red) and DAPI (blue).
Scale bar, 200 mm. The number of lymphatic vessels
per field was counted in tumor sections (n = 15
fields/group).
(B) LLC cells (0.5 3 106) were implanted into
C57Bl/6 mice (n = 5 mice/group). When tumors
reached 500 mm3, treatment with PTX and/or E64
was initiated according to the schedule and doses
described in Experimental Procedures. 3 days later,
tumors were removed and sections were immuno-
stained for podoplanin (red) and DAPI (blue). The
number of lymphatic vessels per field was counted
in tumor sections (n = 15 fields/group). Scale
bar, 200 mm. Error bars indicate SD. *p < 0.05;
**0.01R p > 0.001; ***p% 0.001 (one-way ANOVA
followed by Tukey’s post hoc test).mice treated with PTX, but had little effect on heparanase in
conditioned medium of macrophages from mice treated with
PTX+31C1 (Figure 6C). Indeed, macrophages cultured with
VEGF-C or conditioned medium of macrophages from mice
treated with PTX exhibited an elevated level of cathepsin B, an
effect that was significantly blocked by 31C1 (Figure 6D).
Furthermore, conditioned medium of primary human macro-
phages cultured in the presence of VEGF-C resulted in increased
proteolytic activity, most likely cathepsins, when evaluated for its
ability to degrade sulfate-labeled extracellular matrix (ECM) (Bar-
Ner et al., 1985) compared to conditioned medium from control
macrophages, suggesting that VEGF-C induces protease activ-
ity in human macrophages (Figure 6E). In addition, a significant
increase in cathepsin B expression was also found in 4T1 tumor
sections from mice treated with PTX when compared to mice
treated with PTX+31C1 (Figure 6F). These results further suggest
that macrophages activate exogenous latent heparanase via
cathepsin release, an effect that is most likely regulated by
VEGFR3.
Next, to further test whether cathepsin release from macro-
phages following PTX therapy is primarily regulated by VEGFR3,
we performed a bone marrow transplantation experiment in
which heparanase / mice were transplanted with wild-type
BMDCs (Hep/BMwt) and wild-type mice were transplanted
with BMDCs from heparanase / mice (WT-BMhep/). After(E) Human primary macrophages obtained from peripheral blood (n = 4), as desc
VEGF-C (1 mg/mL) for 3 days. Conditioned medium was obtained and subse
(i.e., release of high-molecular-weight materials from sulfate-labeled ECM [fracti
(F) BALB/c mice were orthotopically implanted with 4T1 cells (n = 5/group). When
of the two drugswas initiated. After 3 days,micewere sacrificed, and tumorswere
DAPI (blue). Scale bar, 200 mm. Error bars indicate SD.
*p < 0.05; **0.01R p > 0.001; ***p% 0.001 (one-way ANOVA followed by Tukey
1352 Cell Reports 17, 1344–1356, October 25, 2016full BMDC reconstitution (Figure S5A), mice were implanted
with LLC cells, and when tumors reached 500 mm3, treatment
with PTX and/or 31C1was initiated. After 3 days, tumorswere re-
sected and tumor sections were stained for lymphatic vessels.
The lymphatic vessel phenotype serves as an indication of
cathepsin release by BMDCs and subsequent heparanase acti-
vation. In this experimental design, WT-BMhep/ mice lack
endogenous heparanase in BMDCs. Therefore, cathepsin
release by BMDCs will activate heparanase derived from cells
other than BMDCs. In contrast, the Hep/BMwt mice lack hep-
aranase in all cells other than BMDCs. We found that
Hep/BMwt mice treated with PTX exhibited a lymphatic vessel
phenotype similar to that of mice treated with PTX+31C1, as
demonstrated by immunostaining with either LYVE-1 or podo-
planin; specifically, lymphatic vessels were located at the tumor
periphery. However, the lymphatic vessel phenotype in WT-
BMhep/ mice recapitulated the same phenotype observed in
wild-type mice; specifically, following PTX therapy the lymphatic
vessels were located at the center of the tumor, whereas
following treatment with PTX+31C1, the lymphatic vessels
were located at the tumor periphery (Figures 7A and S5B). These
results indicate that the cleavage of latent heparanase by ca-
thepsins is regulated in part by VEGFR3. Furthermore, plasma
VEGF-C levels were assessed 24 hr after non-tumor-bearing
heparanase / and wild-type mice were treated with PTX.ribed in Experimental Procedures, were cultured with or without recombinant
quently supplemented with latent heparanase (1 mg/mL). Protease activity
ons 3–15]) was determined (Bar-Ner et al., 1985).
tumors reached a size of 500 mm3, treatment with PTX, 31C1, or a combination
sectioned and immunostained for cathepsin B (green). Nuclei were stainedwith
’s post hoc test).
While levels of plasma VEGF-C were significantly higher in wild-
type mice following PTX therapy, in heparanase / mice, no
significant difference in plasma VEGF-C levels was observed be-
tween treated groups (Figure S5C).
We also assessed the contribution of cathepsins to lymphan-
giogenesis using the cathepsin inhibitor E64. LLC tumors
were implanted in C57Bl/6 mice, and when tumors reached
500 mm3, treatment with PTX, E64, or the combination of the
two drugs was initiated. After 3 days, tumors were removed,
and tumor sections were stained for lymphatic vessels (using
either LYVE-1 or podoplanin). The number of lymphatic vessels
in mice treated with E64 was dramatically reduced regardless
of PTX therapy. Taken together, these results further indicate
that cathepsins are major contributors to tumor lymphangiogen-
esis following PTX therapy, probably via the induction of
heparanase activity (Figures 7B and S5D).
DISCUSSION
Breast cancer metastasizes primarily via the lymphatic system
and the extent of lymph node involvement is a key prognostic
factor (Schoppmann et al., 2004). Upregulation of VEGF-C
within tumors in response to various signals leads to the devel-
opment of a vast lymphatic network, promoting metastatic
spread (Alitalo and Carmeliet, 2002; Mandriota et al., 2001; Ni
et al., 2013; Skobe et al., 2001). Here, we show that the
VEGF-C/VEGFR3 axis is significantly active following PTX
chemotherapy among other drugs. PTX increases the levels of
circulating VEGF-C in both patients andmousemodels, resulting
in enhanced lymphangiogenesis. An increased number of
lymphatic vessels and their location at the center of the tumor
highlight the morphological and biological changes occurring
in lymphatic vessels following chemotherapy. LECs exposed to
plasma from PTX-treated mice become invasive and migratory,
effects that are largely mediated by VEGF-C. As such, the host
pro-metastatic effects occurring in response to PTX therapy
(Gingis-Velitski et al., 2011) are mediated, at least in part, by
VEGF-C.
Macrophages are known to promote tumor angiogenesis, re-
growth, and resistance to therapy (Chung et al., 2009; De Palma
and Lewis, 2013). It has been shown that macrophages secrete
cathepsins in response to PTX therapy, thereby promoting tumor
resistance (Shree et al., 2011). Recently, macrophages were
shown to reside at the perivascular site and promote tumor
revascularization following chemotherapy (Hughes et al., 2015).
Macrophages can also induce lymphangiogenesis and thus sup-
port tumor metastasis via the lymphatic system (Kim et al., 2009;
Shi et al., 2012). We demonstrate that in response to PTX ther-
apy, macrophage activity is regulated by the VEGF-C/VEGFR3
pathway. The number of macrophages in PTX-treated tumors
is significantly higher than in vehicle control treated tumors.
The initial activation of VEGFR3 in macrophages by systemic
VEGF-C overexpression in PTX-treated mice amplifies the
expression of VEGF-C in the treated tumor microenvironment
and, as a result, increases lymphangiogenesis. Specifically,
VEGFR3-expressing macrophages secrete cathepsins that,
among other tasks, convert latent heparanase into its active
form. Heparanase is an endoglycosidase that cleaves heparansulfate (HS) side chains of HS proteoglycans in the ECM and
on the cell surface (Arvatz et al., 2011). High levels of active hep-
aranase closely associate with tumor growth and metastasis, in
part by inducing lymphangiogenesis (Cohen-Kaplan et al., 2008).
Moreover, heparanase levels are elevated in response to anti-
cancer treatments (Shafat et al., 2007). In our study, we show
that active heparanase is significantly elevated in the condi-
tioned medium of macrophages obtained from mice treated
with chemotherapy. Tumor-bearing chimeric mice, whose
bone marrow is heparanase deficient, exhibit a lymphatic vessel
phenotype following treatment with PTX identical to that
observed in tumors from wild-type mice treated with PTX.
Furthermore, blocking the VEGFR3 pathway by the addition of
31C1 antibody to PTX inhibits the processing of latent exoge-
nous heparanase. These results suggest that heparanase is a
secondary downstream mediator of chemotherapy-induced
metastasis via lymphangiogenesis and that these effects are
regulated by VEGFR3 expressed on macrophages.
Of particular importance are the findings that tumor cells co-
implanted with macrophages obtained from PTX-treated mice
exhibit a lymphatic vessel phenotype similar to that of tumors
grown in PTX-treated mice. Previous studies indicate that M2
macrophages may account for lymphangiogenesis (Jung et al.,
2015; Watari et al., 2014). We have previously shown that
following PTX therapy, the balance between M1 and M2 macro-
phages is disrupted in tumors. The blockade of interleukin 1b
(IL-1b) in PTX-treated mice results in an increased number of
infiltrating M2 macrophages in tumors, leading to increased
metastasis (Voloshin et al., 2015). Thus, the specificmacrophage
state that contributes to tumor lymphangiogenesis following PTX
therapy remains to be established. It should be noted that in our
co-implantation experiment, the tumors were never exposed to
chemotherapy. Thus, these results indicate that the lymphatic
vessel phenotype in tumors is mostly mediated by the activity
of macrophages in response to therapy. Furthermore, the
lymphatic vessel phenotype in tumors co-implanted with
macrophages from PTX mice was reversed when compared
to co-implantation of tumor cells with macrophages from
PTX+31C1-treated mice, further indicating that the effect of
lymphatic vessels in tumors is mediated by VEGFR3-expressing
macrophages. Moreover, a single dose of anti-VEGFR3 had little
effect on lymphangiogenesis in unperturbed tumors, implicating
the additional role of VEGFR3 pathways in host cells other than
LECs, and thus, the primary effect of blocking the VEGF-C/
VEGFR3 axis in activated macrophages following PTX therapy
is associated with lymphangiogenesis.
In summary, this study suggests that the blockade of the
VEGF-C/VEGFR3 axis reduces the contribution of lym-
phangiogenesis to metastasis following chemotherapy in
two distinct pathways: (1) it directly affects LEC activity in
tumors, and (2) it indirectly affects lymphangiogenesis by down-
regulating cathepsin release from macrophages, which is other-
wise increased in response to chemotherapy. Currently, both
VEGFR3 blocking antibodies (IMC-3C5) and heparanase inhibi-
tors (SST0001, M402, PI-88, and PG545) are in various stages
of clinical trial evaluation, and their efficacy with or without stan-
dard chemotherapy in large patient cohorts is yet to be deter-
mined (http://clinicaltrials.gov). Based on our results, it wouldCell Reports 17, 1344–1356, October 25, 2016 1353
be of interest to evaluate the clinical outcome of using anti-
VEGFR3 antibodies or heparanase inhibitors in combination
with chemotherapy in a neoadjuvant treatment setting, when
primary tumors are still intact. At this point, the induction of lym-
phangiogenesis in chemotherapy-treated tumors can be mini-
mized or even negated by blocking VEGFR3 or heparanase, in
part by blocking macrophage activity in tumors. This strategy
may potentially inhibit metastatic spread.
EXPERIMENTAL PROCEDURES
Cell Lines
Murine LLC, 4T1 murine mammary adenocarcinoma, and A549 human lung
carcinoma cell lines were purchased from the American Type Culture Collec-
tion (ATCC) and used within 6 months after thawing. LM2-4, a metastatic
variant of the MDA-MB-231 human breast carcinoma line (Munoz et al.,
2006), was kindly provided by Dr. R.S. Kerbel (Toronto, ON, Canada). LLC cells
were grown in DMEM. 4T1, A549, and LM2-4 cells were grown in RPMI-1640
medium. Culture media were supplemented with 10% fetal calf serum, 1%
L-glutamine, 1% sodium pyruvate, and 1% streptomycin, penicillin, and
neomycin in solution (10 mg/mL; Biological Industries). LECs were purchased
from Lonza and cultured on fibronectin-coated plates (10 mg/mL; Biological
Industries) with endothelial cell basal medium (EGM; Lonza).
Tumor Models
The use of animals and experimental protocols were approved by the
Animal Care and Use Committee of the Technion. 4T1 (5 3 105 cells) and
LM2-4 (2 3 106 cells) breast carcinoma cells were implanted orthotopically
into the mammary fat pad of 8- to 10-week-old BALB/c and CB.17 SCID
female mice, respectively (Harlan). Tumor volume was measured regularly
using Vernier calipers according to the formula width2 3 length 3 0.5. LLC
(5 3 105 cells), and A549 (5 3 106 cells) cells were implanted subcutaneously
to the flanks of 8- to 10-week-old C57Bl/6 mice and CB.17 SCIDmice, respec-
tively. In some experiments, heparanase / and their wild-type counterpart
mice (Zcharia et al., 2009) (grown in-house at the Technion) were implanted
with LLC cells.
Drugs and Drug Concentrations
PTX (Biolyse Pharma) was injected intraperitoneally at a dose of 25 mg/kg
(BALB/c and CB.17 SCID mice) or 50 mg/kg (C57Bl/6 mice) as previously
described (Shaked et al., 2008). Vehicle control contained Cremophor EL
(527 mg/mL) and 49.7% alcohol (v/v). In some experiments, non-tumor-
bearing BALB/c mice were injected with gemcitabine (500mg/kg), cisplatinum
(6mg/kg), and FOLFOX, which is a combination of folinic acid (30mg/kg), 5-FU
(50 mg/kg), and oxaliplatin (14 mg/kg), as previously described (Alishekevitz
et al., 2014; Shaked et al., 2008). In cell culture, PTX was used at a concentra-
tion of 170 ng/mL. Anti-mouse VEGFR3 (31C1), anti-mouse VEGFR2 (DC101),
and anti-mouse VEGFR1 (MF1) blocking antibodies (kindly provided by Eli Lilly)
were injected intraperitoneally at a dose of 800 mg/mouse as previously
described (Hoshida et al., 2006; Laakkonen et al., 2007; Shaked et al.,
2005). In some experiments, immunoglobulin rat-IgG antibodies (Jackson
ImmunoResearch) were used as an isotype control. Purified VEGF-C protein,
generated as described previously (Kirkin et al., 2001), was tested for purity,
activity, and endotoxin levels and injected intraperitoneally at a concentration
of 50 mg/mouse per day for 3 consecutive days. For in vitro experiments,
VEGF-C was added to medium at a concentration of 1 mg/mL. In cell culture,
31C1 antibody was added at a concentration of 10 mg/mL as previously
described (Wang et al., 2004). E64 (Sigma-Aldrich), a cathepsin inhibitor,
was injected intraperitoneally at a dose of 100 mg/mouse per day before PTX
administration for 3 sequential days (Navab et al., 1997).
Bone Marrow Transplantation
Bone marrow transplantation was performed as previously described (Vo-
loshin et al., 2015). Details are provided in Supplemental Experimental
Procedures.1354 Cell Reports 17, 1344–1356, October 25, 2016Flow-Cytometry Acquisition and Analysis
Single-cell suspensions of tumor tissue or peritoneal macrophages were
analyzed by flow cytometry in order to evaluate the percentage of LECs, mac-
rophages, and cells expressing VEGR3. Details are provided in Supplemental
Experimental Procedures.
Evaluation of Murine and Human VEGF-C Protein Levels
Blood, BMDCs, organs, and macrophages from murine origin and blood
specimens from human origin were evaluated for VEGF-C levels using specific
ELISAs. The human study was approved by the ethic committees both at
Haemek and at Rambammedical centers, and all patients signed an informed
consent. Details are provided in Supplemental Experimental Procedures.
Invasion and Migration Assays
The invasion and migration properties of LECs were assessed using the
Boyden chamber assay as previously described (Gingis-Velitski et al., 2011).
Details are provided in Supplemental Experimental Procedures.
Tube-Forming Assay
Tube formation of LECs on Matrigel was carried out as previously described
(Varshavsky et al., 2008). Details are provided in Supplemental Experimental
Procedures.
Immunostaining
Lungs or tumors were embedded in O.C.T. (Sakura) and subsequently frozen
at 80C. Tissue sections (12 mm thick) were prepared using Leica CM 1950
microtome (Leica Microsystems) in order to detect lymphatic vessels, endo-
thelial cells, or metastasis lesions. In some experiments, human tumor speci-
mens were embedded in paraffin, sectioned (6–10 mm thick), and stained for
VEGF-C. Details are provided in Supplemental Experimental Procedures.
Macrophage Depletion Using Clodronate Liposomes
For depletion of macrophages, mice were injected intraperitoneally with
200 mL liposomal clodronate (clodrolip) or control liposomes (Macrophage
depletion kit, Mannosylated; Encapsula NanoSciences) according to the man-
ufacturer’s instructions 72 hr before treatment with PTX and/or 31C1.
Cathepsin and Heparanase Activity Assay
Macrophages obtained from vehicle or PTX-treated BALB/c mice were har-
vested and cultured in serum-free media. Conditioned medium and cells
were evaluated for cathepsin and heparanase activity as described in detail
in Supplemental Experimental Procedures.
Statistical Analysis
Data are presented as mean ± SD. The number of replicates for each experi-
ment is provided in Supplemental Experimental Procedures and/or the figure
legends. In the in vitro experiments, an estimate of variance was performed,
and parameters for the statistical test were adjusted accordingly. In the in vivo
and ex vivo studies, three to eight mice per group (as specified in the figures)
were used to reach statistical significance. The sample size for each experi-
ment was designed to have 80% power at a two-sided a of 0.05. To calculate
mouse survival, a Kaplan-Meier survival curve statistical analysis was per-
formed in which the uncertainty of the fractional survival of 95% confidence in-
tervals was calculated. A two-tailed Student’s t test for a comparison between
two groups or one-way ANOVA followed by Tukey’s ad hoc statistical test for a
comparison between multiple groups was used. For human studies, a paired
two-tailed Student’s t test was used to make comparisons between baseline
and post-therapy. In all experiments, statistical significance was calculated
using GraphPad/Prism5. Differences among all groups were compared and
considered significant at values below 0.05.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and five figures and can be found with this article online at http://dx.doi.org/
10.1016/j.celrep.2016.09.083.
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